Dna Test For Breast Cancer Risk Draws Criticism

摘要

It's been 8 years since the human genome was sequenced with the promise of revolutionizing medicine, and since then, efforts to put DNA discoveries into the doctor's office have only grown more controversial. The latest tussle came last week after deCODE Genetics, an Icelandic company, released the first-ever breast cancer risk test designed to cover common forms of the disease. The rollout and reaction were predictable: deCODE hailed the test as offering women a chance to take advantage of more aggressive screening if they're found at higher risk. Many oncologists and geneticists decried the $1625 test as premature because it includes just seven genetic variants out of the dozens or hundreds driving breast cancer that scientists expect to find soon.